PubMed Health⌕ Search

PubMed · 10487513

Hormonal contraception and epilepsy.

Abstract

Attempts to normalize lifestyle and optimize quality of life in women with epilepsy should include the option of a reliable method of birth control, including oral contraceptives (OCs). Despite the well-known effects of estrogen on lowering seizure threshold, it has never been shown that estrogen-containing OCs worsen seizures in epileptic patients. In theory, the presence of progesterone (which is known to inhibit seizures experimentally) in OCs could counterbalance the seizure-promoting effects of estrogen. However, there is evidence that some OCs may fail when combined with antiepileptic drugs (AEDs), possibly because of the latters' inducing effects on endogenous estradiol and progesterone. Physicians have a duty to offer appropriate and accurate counseling to epileptic patients concerning optimal choice in the use of OCs for those considering this method of contraception. Recommendations include possible use of a noninducing AED, or (for patients taking inducing AEDs) use of an OC containing > or = 50 microg estrogen. Patients should be warned that midcycle bleeding indicates possible OC failure and that the absence of such bleeding is not an indication of OC effectiveness. Additional contraceptive measures are also advised.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Guberman. 1999. Hormonal contraception and epilepsy.. https://pubmed.ncbi.nlm.nih.gov/10487513/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗